<DOC>
	<DOCNO>NCT00786240</DOCNO>
	<brief_summary>The objective study demonstrate bioequivalence 4 mg tablet formulation D formulation E ( 1 ) .</brief_summary>
	<brief_title>Phase1 , Single Dose , Crossover Study Determine Bioequivalence</brief_title>
	<detailed_description />
	<mesh_term>Fesoterodine</mesh_term>
	<criteria>Healthy male female Chinese Japanese subject Evidence history clinically significant finding screen</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>September 2010</verification_date>
	<keyword>Bioequivalence</keyword>
	<keyword>Therapeutic Equivalency</keyword>
</DOC>